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Abstract
Background
We investigated the recent 10-year trends in the number of patients with atrial fibrillation
(AF) undergoing percutaneous coronary intervention (PCI) in relation to prescription pat-
terns of antithrombotic therapy.
Methods
We analyzed the annual prevalence of PCI and patterns of antithrombotic therapy after PCI,
including antiplatelets and oral anticoagulants (vitamin K antagonists and non-vitamin K
antagonist oral anticoagulants [NOACs]), in patients with AF between 2006 and 2015 by
using the Korean National Health Insurance Service database. Independent factors associ-
ated with triple therapy (oral anticoagulant plus dual antiplatelet) prescription were assessed
using multivariable logistic regression analysis.
Results
The number of patients with AF undergoing PCI increased gradually from 2006 (n = 2,140)
to 2015 (n = 3,631) (ptrend<0.001). In 2006, only 22.7% of patients received triple therapy
after PCI although 96.2% of them were indicated for anticoagulation (CHA2DS2-VASc score
�2). The prescription rate of triple therapy increased to 38.3% in 2015 (ptrend<0.001), which
was mainly attributed to a recent increment of NOAC-based triple therapy from 2013 (17.5%
in 2015). Previous ischemic stroke or systemic embolism, old age, hypertension, and
congestive heart failure were significantly associated with a higher triple therapy prescription
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rate, whereas previous myocardial infarction, PCI, and peripheral arterial disease were
associated with triple therapy underuse.
Conclusions
From 2006 to 2015, the number of patients with AF undergoing PCI and the prescription
rate of triple therapy increased gradually with a recent increment of NOAC-based antithrom-
botic therapy from 2013. Previous myocardial infarction, peripheral artery disease, and PCI
were associated with underuse of triple therapy.
Introduction
Atrial fibrillation (AF) is a disorder with an increasing prevalence. Because it confers signifi-
cant cardiovascular morbidity and mortality from stroke and thromboembolism [1], the
guidelines recommend oral anticoagulants (OACs) as a preventive strategy in patients with AF
with a moderate to high risk of developing stroke [2–4]. Among patients with AF, 5–15% are
known to undergo percutaneous coronary intervention (PCI) during their entire lifespan [2],
and approximately 5–10% of patients undergoing PCI have concomitant AF [5]. Patients with
coronary artery disease (CAD) undergoing PCI and stent implantation need to be treated with
dual antiplatelet agents (aspirin and P2Y12 antagonists) to reduce the risk of stent thrombosis.
Therefore, patients with AF undergoing PCI and stent implantation are recommended to
receive combination antithrombotic therapy including OACs and antiplatelets. However,
there are concerns about the clinical benefit of intensive combination antithrombotic therapy,
as it increases the risk of fatal bleeding, which would offset the benefit in reducing the ischemic
risk [6–9]. As non-vitamin K antagonist oral anticoagulants (NOACs) had shown a safety ben-
efit in patients with AF compared with conventional vitamin K antagonists (VKAs) [10,11],
recent clinical trials have investigated the clinical benefit of dual antithrombotic therapy com-
bining NOAC and P2Y12 antagonists (mostly clopidogrel) as an alternative to triple therapy
after PCI in patients with AF [12–15]. However, there is a paucity of data providing real-world
evidence for the prescription patterns of antithrombotic therapy among patients with AF after
PCI, especially among the Asian population. Therefore, we investigated the recent 10-year
trends in the number of patients with AF undergoing PCI in relation to antithrombotic ther-
apy by using the Korean National Health Insurance database.
Materials and methods
Study population and data source
The study population and clinical data were extracted from the National Health Claims Data-
base established by the Korean National Health Insurance Service (NHIS) [16,17]. The NHIS
system provides comprehensive medical care coverage to 97% of the Korean population, and
maintains a database comprising inpatient and outpatient medical service records, diagnostic
and procedural codes, prescribed medication claims, and patients’ demographic data. The
Medical Aid program covers the low-income population (the remaining 3%). From 2006, the
clinical data recorded by the Medical Aid program have been included in the NHIS database;
thus, the NHIS claims database represents the entire Korean population. On the basis of the
International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM)
codes, we analyzed the data of all Koreans aged�20 years between January 2006 and
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Definitions of non-valvular atrial fibrillation, comorbidities, and
percutaneous coronary intervention
Non-valvular AF was defined as in previous reports [1,18,19]. Patients diagnosed as having AF
during hospitalization or those with�2 diagnoses in outpatient clinics were included. The
diagnostic codes for AF were I480–I484 and I489 (ICD-10-CM codes). Patients with mitral
stenosis (I50, I52, and I59) or mechanical heart valves (Z952–Z954) were excluded. The
detailed definitions of comorbidities are summarized in S1 Table. Briefly, hypertension and
diabetes mellitus were defined based on a combination of diagnostic codes and the use of at
least 1 antihypertensive or antidiabetic drug, respectively. Heart failure, previous stroke or
thromboembolism, myocardial infarction (MI), peripheral artery disease (PAD), and intracra-
nial hemorrhage (ICH) were defined based on ICD-10-CM codes [1,18,19]. To assess the
stroke risk of individual patients, we calculated the CHA2DS2-VASc scores by assigning 1
point for age between 65 and 74 years, female sex, and the presence of hypertension, diabetes
mellitus, heart failure, and vascular disease (previous MI or PAD), and 2 points for previous
stroke/transient ischemic attack/thromboembolism or age�75 years [20]. Patients with a high
stroke risk were defined as those with a CHA2DS2-VASc score of�2. The procedure codes for
PCI (M6561, M6562, M6563, and M6564) were used for patients who had undergone PCI dur-
ing the study period. For those who had undergone multiple PCI procedures in separate years,
each procedure was counted separately.
Antithrombotic therapy
We reviewed the inpatient and outpatient prescription records of antithrombotic therapy
including aspirin, clopidogrel, VKAs, and NOACs annually from 2006 to 2015. However, as
edoxaban was introduced in Korea only in 2016, it was not included under the NOACs regi-
men in our analysis. Additionally, newer P2Y12 inhibitors such as prasugrel and ticagrelor
were not included in our analysis because they were not widely available in Korea during our
study period. According to the prescription of antithrombotic therapy, patients were catego-
rized into the following groups: no treatment, single antiplatelet therapy (SAPT), OAC mono-
therapy, dual antiplatelet therapy (DAPT), dual therapy with OAC and SAPT, VKA-based
triple therapy, and NOAC-based triple therapy.
Statistical analysis
The total numbers of patients with AF and those who underwent PCI, the total number of PCI
procedures, and the prescription regimen of antithrombotic therapy after PCI were investi-
gated on a yearly basis. The baseline characteristics of the study population including demo-
graphic information and comorbidities were also investigated annually. Categorical variables
were presented as numbers and percentages, whereas continuous data were described as
means with standard deviations. The significance of linear time trends over the entire study
period was assessed using logistic and linear regression models. Subgroup analyses for the
trends in prescription patterns of antithrombotic therapy were performed according to sex
and for patients at a high risk of stroke (CHA2DS2-VASc score�2).
To investigate the clinical factors associated with underuse of triple therapy after PCI in
patients with AF, baseline characteristics were compared between patients with triple therapy
and those with only DAPT after PCI among the total population in 2015. Multivariate logistic
Antithrombotic treatment in AF population undergoing PCI
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regression analysis was applied to identify factors independently associated with underuse of
triple therapy. Trends in the prescription rate of triple therapy according to CHA2DS2-VASc
scores were assessed using logistic regression analysis. Statistical significance was set at two-
tailed p-values of<0.05. Statistical analyses were performed using SAS software version 9.3
(SAS Institute, Cary, NC, USA).
Results and discussion
Baseline characteristics of the study population
The total number of patients with AF undergoing PCI increased gradually from 2,140 in 2006
to 3,631 in 2015 (ptrend<0.001), although the number of PCI procedures per patient decreased
slightly (1.19±0.42 in 2006 to 1.16±0.40 in 2015) (Table 1 and Fig 1). Among patients who had
undergone PCI in 2015 (n = 53,280), approximately 7% had concomitant AF. The mean patient
age increased from 66.3±10.5 years in 2006 to 70.8±10.5 years in 2015 (ptrend<0.001), with the
percentage of those aged�75 years being 41.3% in 2015. Approximately 60% of patients
throughout the study period were men. The prevalence of diabetes mellitus and congestive
heart failure increased during 10 years (40.3% in 2015 for diabetes mellitus [ptrend<0.001] and
58.3% in 2015 for congestive heart failure [ptrend<0.001]) (Table 1 and S1 Fig). In each year,
>90% of the patients were at a high risk of stroke (CHA2DS2-VASc score�2).
Ten-year temporal trends in antithrombotic treatment regimens in
patients with atrial fibrillation undergoing percutaneous coronary
intervention
In 2006, 75.5% of patients received DAPT, whereas only 22.7% were prescribed triple therapy
with VKAs. However, the percentage of those with triple therapy increased to 38.3% in 2015
(ptrend<0.001), which was mainly attributed to a recent increment of NOAC-based triple ther-
apy from 2013, comprising 45.8% of the overall triple therapy in 2015 (ptrend<0.001) (Table 2
and Fig 2A). These trends were also similar among patients at a high risk of stroke (38.8% for
triple therapy in 2015) (Fig 2B), and in both sexes (37.7% and 39.2% for triple therapy in 2015
for male and female patients, respectively) (Fig 2C and 2D).
Risk factors associated with underuse of triple antithrombotic therapy
With respect to factors associated with prescription of triple therapy after PCI, a history of stroke
or systemic embolism, old age (>65 years), hypertension, and congestive heart failure were inde-
pendently associated with a higher prescription rate of triple therapy (S2 Table and Fig 3). How-
ever, a history of MI, PCI, and PAD was associated with underuse of triple therapy after PCI.
Trends in patients with different risks of stroke
An incremental relationship was observed between CHA2DS2-VASc scores and prescription
of triple therapy (S2 Fig). Patients with a CHA2DS2-VASc score of�4 showed significantly
higher odds for receiving triple therapy after PCI than those with a score of 0 as a reference
(odds ratio [OR] 3.62, 95% confidence interval [CI] 1.06–12.41 for patients with CHA2DS2-
VASc scores of 4).
In this large population-based cohort study, our principal findings were as follows: (1)
the number of patients with AF undergoing PCI increased in the recent 10 years; (2) most
patients with AF undergoing PCI were administered DAPT without concomitant OAC pre-
scription; (3) triple therapy prescription showed a gradual increase over time, being used in
approximately one-third of patients with AF undergoing PCI, particularly after the approval of
Antithrombotic treatment in AF population undergoing PCI
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NOAC in 2013; (4) previous MI, PCI, and PAD were associated with underuse of triple ther-
apy; and (5) there was an incremental relationship between CHA2DS2-VASc scores and triple
therapy prescriptions. To our knowledge, this is the first and largest Asian study to investigate
the temporal trends in the number of patients with AF undergoing PCI in relation to antith-
rombotic therapy.
Prevalence of atrial fibrillation in patients undergoing percutaneous
coronary intervention
Considering the increasing incidence and prevalence of AF [1], the number of patients with
AF undergoing PCI will also increase. Indeed, we observed that approximately 7% of patients
who underwent PCI had AF in 2015, consistent with previous studies [5,21–24]. For example,
a recent Asian study reported that 7% of patients presented with a diagnosis of AF at the index
PCI, and this was associated with an increased risk of ischemia and bleeding complications
[5]. Additionally, patients with AF generally show more severe comorbidities and more
Table 1. Baseline characteristics of the study population.
Years 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 ptrend
Total AF patients 124549 137604 150301 163943 177663 185205 205813 225834 248925 276842 <0.001
AF patients with PCI 2140 (1.7) 2446 (1.8) 2511 (1.7) 2553 (1.6) 2778 (1.6) 2713 (1.5) 2940 (1.4) 3157 (1.4) 3411 (1.4) 3631 (1.3) <0.001
Total PCI procedure 2541 2933 2985 3026 3248 3200 3443 3694 3932 4220 <0.001
Number of PCI per patient 1.19±0.42 1.20±0.43 1.19±0.41 1.19±0.41 1.17±0.39 1.18±0.40 1.17±0.39 1.17±0.39 1.15±0.37 1.16±0.40 <0.001
Demographics
Age, years 66.3±10.5 67.1±10.3 67.6±10.4 68.9±10.0 69.0±10.2 70.1±9.8 70.2±10.3 70.1±10.4 70.5±10.8 70.8±10.5 <0.001
Age
65–74 years 839 (39.2) 974 (39.8) 1023
(40.7)
1047
(41.0)
1097
(39.5)
1050
(38.7)
1079
(36.7)
1122
(35.5)
1124
(33.0)
1187
(32.7)
75 years� 472 (22.1) 589 (24.1) 672 (26.8) 790 (30.9) 878 (31.6) 988 (36.4) 1120
(38.1)
1174
(37.2)
1376
(40.3)
1501
(41.3)
Male 1403
(65.6)
1578
(64.5)
1595
(63.5)
1646
(64.5)
1802
(64.9)
1782
(65.7)
1918
(65.2)
2078
(65.8)
2277
(66.8)
2457
(67.7)
<0.001
Comorbidities
Diabetes mellitus 740 (34.6) 850 (34.8) 881 (35.1) 944 (37.0) 1015
(36.5)
1038
(38.3)
1136
(38.6)
1242
(39.3)
1289
(37.8)
1463
(40.3)
<0.001
Hypertension 1984
(92.7)
2239
(91.5)
2296
(91.4)
2297
(90.0)
2457
(88.4)
2364
(87.1)
2566
(87.3)
2779
(88.0)
2951
(86.5)
3098
(85.3)
0.012
Dyslipidemia 1776
(83.0)
2030
(83.0)
2040
(81.2)
2060
(80.7)
2215
(79.7)
2151
(79.3)
2429
(82.6)
2606
(82.6)
2958
(86.7)
3121
(86.0)
<0.001
Congestive heart failure 679 (31.7) 690 (28.2) 791 (31.5) 876 (34.3) 1094
(39.4)
1259
(46.4)
1401
(47.7)
1617
(51.2)
1900
(55.7)
2118
(58.3)
<0.001
Myocardial infarction 1207
(56.4)
1287
(52.6)
1209
(48.2)
1201
(47.0)
1242
(44.7)
1079
(39.8)
1194
(40.6)
1330
(42.1)
1491
(43.7)
1625
(44.8)
<0.001
Peripheral arterial disease 509 (23.8) 518 (21.2) 637 (25.3) 694 (27.2) 664 (23.9) 641 (23.6) 691 (23.5) 726 (23.0) 784 (23.0) 884 (24.4) <0.001
Stroke/TIA/
thromboembolism
613 (28.6) 736 (30.1) 685 (27.3) 710 (27.8) 799 (28.8) 820 (30.2) 912 (31.0) 927 (29.4) 993 (29.1) 1071
(29.5)
<0.001
Intracranial hemorrhage 53 (2.5) 48 (2.0) 57 (2.3) 66 (2.6) 86 (3.1) 80 (3.0) 89 (3.0) 134 (4.2) 132 (3.9) 97 (2.7) <0.001
CHA2DS2-VASc Score 4.3±1.8 4.3±1.8 4.3±1.8 4.5±1.8 4.4±1.9 4.6±1.9 4.7±1.9 4.7±1.9 4.8±1.9 4.8±1.9 <0.001
Score 2� 2058
(96.2)
2345
(95.9)
2410
(96.0)
2458
(96.3)
2646
(95.3)
2604
(96.0)
2851
(97.0)
3063
(97.0)
3294
(96.6)
3528
(97.1)
<0.001
Abbreviations: AF, atrial fibrillation; PCI, percutaneous coronary intervention; TIA, transient ischemic attack
Values are given as mean±standard deviation or number (percentage), unless otherwise indicated.
https://doi.org/10.1371/journal.pone.0209593.t001
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complex CAD at baseline, leading to higher mortality and a higher rate of cardiovascular
events [25,26]. In our results, the mean CHA2DS2-VASc score of the patients increased to 4.8
±1.9 in 2015, and>90% of patients each year had a CHA2DS2-VASc score of�2, which were
higher than those reported in previous studies [5,7]. Although the complexity of CAD was not
evaluated in our study, these results would reflect the higher burden of cardiovascular risk fac-
tors and the severity of disease in our study population.
Antithrombotic therapy in patients with atrial fibrillation undergoing
percutaneous coronary intervention in real-world clinical practice
The current guidelines recommend combination antithrombotic therapy in patients with AF
after PCI with stent implantation [2,3,26,27]. Although the optimal duration and treatment
regimens remain under debate, OAC is considered an essential component in any combina-
tion. However, concomitant prescription of antiplatelets with OAC predisposes patients to a
higher risk of bleeding [7], which could result in early discontinuation of antithrombotic ther-
apy, leading to a higher risk of stent thrombosis. Although non-Asians were reported to have a
lower risk of bleeding associated with the use of OAC than Asians [28], underprescription of
OAC after PCI has also been observed in non-Asian populations. Among the 1648 patients
with AF with non-ST segment elevation MI who underwent PCI in the CRUSADE (Can
Fig 1. The 10-year trends in the number of patients with atrial fibrillation undergoing percutaneous coronary intervention. The number of patients with AF
undergoing PCI steadily increased from 2006 to 2015 (ptrend<0.001) regardless of sex. In each year,>90% of patients were at a high risk of stroke (CHA2DS2-VASc score
�2). AF, atrial fibrillation; PCI, percutaneous coronary intervention.
https://doi.org/10.1371/journal.pone.0209593.g001
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Table 2. Temporal trends of prescription of antithrombotic therapy among patients with atrial fibrillation undergoing percutaneous coronary intervention.
Overall population
Year 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 ptrend
Total patients 2140 2446 2511 2553 2778 2713 2940 3157 3411 3631 <0.001
SAPT 29 (1.4) 10 (0.4) 2 (0.1) 6 (0.2) 6 (0.2) 11 (0.4) 11 (0.4) 22 (0.7) 25 (0.7) 25 (0.7) 0.374
DAPT 1616
(75.5)
1808
(73.9)
1880
(74.9)
1904
(74.6)
1990
(71.6)
1876
(69.1)
2014
(68.5)
2050
(64.9)
2159
(63.3)
2188
(60.3)
<0.001
OAC monotherapy 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.0) 0 (0.0) 1 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.974
Dual therapy (OAC
+APT)
10 (0.5) 4 (0.2) 2 (0.1) 2 (0.1) 13 (0.5) 2 (0.1) 7 (0.2) 14 (0.4) 10 (0.3) 31 (0.9) 0.006
Triple (warfarin) 485 (22.7) 624 (25.5) 627 (25.0) 641 (25.1) 767 (27.6) 820 (30.2) 895 (30.4) 995 (31.5) 1118
(32.8)
752 (20.7) <0.001
Triple (NOAC) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.0) 3 (0.1) 12 (0.4) 76 (2.4) 99 (2.9) 635 (17.5) <0.001
High stroke riska
Year 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 ptrend
Total patients 2058 2345 2410 2458 2646 2604 2851 3063 3294 3528 <0.001
SAPT 28 (1.4) 9 (0.4) 2 (0.1) 6 (0.2) 6 (0.2) 10 (0.4) 10 (0.4) 22 (0.7) 24 (0.7) 23 (0.7) 0.449
DAPT 1556
(75.6)
1729
(73.7)
1804
(74.9)
1832
(74.5)
1884
(71.2)
1788
(68.7)
1937
(67.9)
1977
(64.5)
2068
(62.8)
2106
(59.7)
<0.001
OAC monotherapy 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.0) 0 (0.0) 1 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.979
Dual therapy (OAC
+APT)
10 (0.5) 4 (0.2) 2 (0.1) 2 (0.1) 11 (0.4) 2 (0.1) 7 (0.2) 14 (0.5) 9 (0.3) 31 (0.9) 0.006
Triple (warfarin) 464 (22.5) 603 (25.7) 602 (25.0) 618 (25.1) 743 (28.1) 800 (30.7) 884 (31.0) 975 (31.8) 1096
(33.3)
737 (20.9) <0.001
Triple (NOAC) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.0) 3 (0.1) 12 (0.4) 75 (2.4) 97 (2.9) 631 (17.9) <0.001
Male
Year 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 ptrend
Total patients 1403 1578 1595 1646 1802 1782 1918 2078 2277 2457 <0.001
SAPT 18 (1.3) 6 (0.4) 2 (0.1) 5 (0.3) 4 (0.2) 7 (0.4) 9 (0.5) 13 (0.6) 19 (0.8) 19 (0.8) 0.206
DAPT 1051
(74.9)
1141
(72.3)
1154
(72.4)
1211
(73.6)
1271
(70.5)
1215
(68.2)
1318
(68.7)
1346
(64.8)
1466
(64.4)
1486
(60.5)
<0.001
OAC monotherapy 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) -
Dual therapy (OAC
+APT)
7 (0.5) 1 (0.1) 1 (0.1) 1 (0.1) 7 (0.4) 2 (0.1) 4 (0.2) 10 (0.5) 7 (0.3) 25 (1.0) 0.002
Triple (warfarin) 327 (23.3) 430 (27.2) 438 (27.5) 429 (26.1) 520 (28.9) 556 (31.2) 584 (30.4) 666 (32.1) 721 (31.7) 531 (21.6) 0.001
Triple (NOAC) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.1) 3 (0.2) 43 (2.1) 64 (2.8) 396 (16.1) <0.001
Female
Year 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 ptrend
Total patients 737 868 916 907 976 931 1022 1079 1134 1174 <0.001
SAPT 11 (1.5) 4 (0.5) 0 (0.0) 1 (0.1) 2 (0.2) 4 (0.4) 2 (0.2) 9 (0.8) 6 (0.5) 6 (0.5) 0.735
DAPT 565 (76.7) 667 (76.8) 726 (79.3) 693 (76.4) 719 (73.7) 661 (71.0) 696 (68.1) 704 (65.2) 693 (61.6) 702 (59.8) <0.001
OAC monotherapy 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.1) 0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 0.743
Dual therapy (OAC
+APT)
3 (0.4) 3 (0.3) 1 (0.1) 1 (0.1) 6 (0.6) 0 (0.0) 3 (0.3) 4 (0.4) 3 (0.3) 6 (0.5) 0.685
Triple (warfarin) 158 (21.4) 194 (22.4) 189 (20.6) 212 (23.4) 247 (25.3) 264 (28.4) 311 (30.4) 329 (30.5) 397 (35.0) 221 (18.8) <0.001
Triple (NOAC) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.1) 2 (0.2) 9 (0.9) 33 (3.1) 35 (3.1) 239 (20.4) <0.001
Abbreviations: APT, antiplatelet; DAPT, dual antiplatelet therapy; NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; SAPT single
antiplatelet therapy
Values are given as number (percentage), unless otherwise indicated.
aCHA2DS2-VASc score�2
https://doi.org/10.1371/journal.pone.0209593.t002
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Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early
implementation of the American College of Cardiology/American Heart Association guide-
lines) registry, only 27% (n = 448) of the total population received triple therapy at discharge
[29]. Among 12,165 Danish patients with AF concomitant with acute MI or PCI between 2001
and 2009, only 15% (n = 1,895) received triple therapy [30]. This number is even lower in the
Asian population, with a recent registry reporting that only 10% of patients with AF who had
PCI and drug-eluting stent implantation received triple therapy at discharge [5]. In the current
nationwide study, we found that the prescription rate of triple therapy showed a gradual incre-
ment in the recent 10 years. Nevertheless, the percentage of patients receiving triple therapy
after PCI was only 38.2% in 2015. Previously, we reported that female sex, prior vascular dis-
ease, and ICH were associated with underuse of OAC in the entire Korean population with AF
[31]. Similarly, in the current study, a history of vascular disease such as MI or PAD, and a pre-
vious PCI event were associated with underuse of triple therapy in patients with AF after PCI.
We inferred that the requirement for antiplatelet therapy in these patients would discourage
physicians from combining OAC with antiplatelets after PCI. These trends could be related to
concerns about the increased bleeding risk when prescribing OAC among patients with MI or
those receiving antiplatelet therapy [32]. However, Pastori et al. [33] have shown a significantly
higher risk of adverse cardiovascular events in patients with AF with concomitant PAD (haz-
ard ratio [HR] 1.8, 95% CI 1.1–2.9), CAD (HR 2.2, 95% CI 1.4–3.4), or both (HR 2.4, 95% CI
Fig 2. Temporal trends in antithrombotic treatment in patients with atrial fibrillation undergoing percutaneous coronary intervention. The 10-year
trends in prescription patterns of antithrombotic therapy among patients with AF undergoing PCI are presented among the total population (a), those at high
risk of stroke (CHA2DS2-VASc score�2) (b), and both male (c) and female (d) patients. Patients who received SAPT, OAC monotherapy, and dual therapy
with OAC and SAPT were grouped into other types of antithrombotic therapy, as the prescription rates were very low. AF, atrial fibrillation; PCI, percutaneous
coronary intervention; DAPT, dual antiplatelet therapy; NOAC, non-vitamin K antagonist oral anticoagulants.
https://doi.org/10.1371/journal.pone.0209593.g002
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1.4–4.4) than in those without any risk factors, suggesting that more optimized antithrombotic
therapy is necessary for these patients. Interestingly, we found a significant increase in the pre-
scription of triple therapy after PCI among patients with AF who had a CHA2DS2-VASc score
of�4. This result also implies that the threshold for the initiation of OAC in clinical practice is
much higher for patients with AF after PCI than in the general AF population.
Role of non-vitamin K antagonist oral anticoagulants in antithrombotic
therapy among patients with atrial fibrillation undergoing percutaneous
coronary intervention
As NOACs had shown clinical benefits compared with VKAs among patients with AF, clinical
trials investigating the benefit of NOAC-based antithrombotic therapy in patients with AF
Fig 3. Factors associated with prescriptions of triple therapy. History of stroke or systemic embolism, old age (>65 years), hypertension, and congestive heart failure
were significantly associated with higher prescriptions of triple therapy after PCI. However, histories of peripheral artery disease, PCI, and myocardial infarction were
associated with underuse of triple therapy. CI, confidence interval; OR, odds ratio; PCI, percutaneous coronary intervention.
https://doi.org/10.1371/journal.pone.0209593.g003
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undergoing PCI have been conducted [12,13]. The PIONEER AF-PCI (Open-label, Random-
ized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a
Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects with Atrial Fibrilla-
tion Who Undergo Percutaneous Coronary Intervention) trial [12] showed that the rates of
clinically significant bleeding episodes were lower in patients administered NOAC-based
antithrombotic therapy (rivaroxaban 15 mg once daily combined with a P2Y12 inhibitor over
12 months or 2.5 mg twice daily combined with DAPT) than in those administered VKA-
based triple therapy (16.8%, 18.0%, and 26.7%, respectively). Additionally, the RE-DUAL
(Randomized Evaluation of Dual Antithrombotic Therapy with Dabigatran vs. Triple Therapy
with Warfarin in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Cor-
onary Intervention) trial [13] compared the safety outcomes between dabigatran-based antith-
rombotic therapy and VKA-based triple therapy in patients with AF undergoing PCI, and
showed that those receiving dabigatran had significantly lower rates of subsequent bleeding
risks. Furthermore, 2 randomized clinical trials investigating the safety and efficacy of antith-
rombotic therapy based on apixaban [14] or edoxaban [15] combined with P2Y12 inhibitors
vs. triple therapy with conventional VKA are ongoing. Of note, the recent European Society of
Cardiology guidelines have been updated and recommend the use of dual therapy with OAC
plus clopidogrel 75 mg/day as an alternative to 1-month triple antithrombotic therapy in
patients in whom the risk of bleeding outweighs the risk of ischemia [4].
Limitations
While this study covers nationwide data of the entire Korean population, some limitations are
evident. Information about individual patients’ drug compliance, clinical information about
contraindications to OACs use based on the assessment of bleeding risk, and laboratory data
including time in therapeutic range in patients using VKAs were not available. The current
study included prescription records of antithrombotic therapy until 2015; therefore, the trends
from 2016 cannot be presented. However, as the current study showed an incremental trend
of NOAC-based antithrombotic therapy especially from 2013, we can presume an even higher
prescription rate after 2016. Finally, the long-term clinical efficacy and safety outcomes in
patients with AF undergoing PCI according to the different antithrombotic therapy regimens
were not included in our results and need to be further investigated.
Conclusions
From 2006 to 2015, an increasing trend in the number of patients with AF undergoing PCI
was observed. The prescription rate of triple therapy after PCI had increased gradually, despite
remaining <40%, with a recent increment of NOAC-based antithrombotic therapy from 2013.
Previous MI, PAD, and PCI were associated with underuse of triple therapy.
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